Small Intestinal Bacterial Overgrowth (SIBO)

Overview

Small intestinal bacterial overgrowth (SIBO) is a condition in which an abnormally high number of bacteria colonize the small intestine, the part of the gut that normally contains relatively few microbes compared with the colon. The excess bacteria ferment the food you eat, producing gases and metabolites that can irritate the intestinal lining and interfere with nutrient absorption.

Who it affects: While SIBO can occur at any age, it is most commonly diagnosed in adults aged 30‑65. Women are diagnosed slightly more often than men (approximately 60% vs 40% in most studies). Certain populations—people with irritable bowel syndrome (IBS), diabetes, celiac disease, inflammatory bowel disease, and those who have undergone abdominal surgery—are at markedly higher risk.

Prevalence: Epidemiologic data suggest that SIBO may affect up to 5‑15% of the general population, but prevalence climbs to 30‑40% among individuals with IBS and 70% in patients with longstanding gastrointestinal motility disorders (e.g., chronic pseudo‑obstruction). Because the condition is often under‑recognized, the true prevalence is likely higher.

Symptoms

Symptoms arise from bacterial fermentation, gas production, and malabsorption. They can be intermittent and vary in severity.

• Abdominal bloating – a sensation of fullness or visible distention, often worse after meals.
• Flatulence – frequent, often odorous gas release.
• Abdominal pain or cramping – usually localized in the upper abdomen but may be diffuse.
• Diarrhea – watery stools, urgency, and sometimes nocturnal episodes.
• Constipation – some patients experience alternating bowel habits.
• Steatorrhea (fatty stools) – pale, greasy stools that float, indicating malabsorption of fat.
• Weight loss or difficulty gaining weight – due to poor nutrient absorption.
• Nutrient deficiencies – especially vitamin B12, iron, calcium, magnesium, and fat‑soluble vitamins (A, D, E, K).
• Fatigue and brain fog – likely related to both nutrient deficiencies and systemic inflammation.
• Acid reflux or heartburn – bacterial overgrowth can increase gas pressure, promoting reflux.
• Joint or muscle aches – some patients report generalized aches, possibly linked to inflammation.

Causes and Risk Factors

SIBO typically results from a disruption in the normal defenses that keep bacterial populations low in the small intestine.

Mechanisms that lead to bacterial overgrowth

• Impaired intestinal motility – The “migrating motor complex” (MMC) sweeps residual food and bacteria downstream during fasting. Conditions that slow MMC (e.g., diabetes neuropathy, scleroderma, opioid use) permit bacterial proliferation.
• Structural abnormalities – Surgical bypasses, strictures, diverticula, or blind loops create stagnant pockets where bacteria can thrive.
• Reduced gastric acid – Proton‑pump inhibitors (PPIs) and achlorhydria decrease the stomach’s bactericidal effect.
• Immune dysfunction – IgA deficiency, HIV, or immunosuppressive therapies diminish mucosal immunity.
• Altered intestinal flora – Broad‑spectrum antibiotics or severe dysbiosis can allow overgrowth of fermenting organisms such as *Escherichia coli*, *Klebsiella*, *Clostridium* spp., or methanogenic archaea (*Methanobrevibacter smithii*).

Risk factors

• History of abdominal or pelvic surgery (e.g., gastric bypass, ileal resection)
• Chronic pancreatitis or exocrine pancreatic insufficiency
• Diseases that affect motility: diabetes mellitus, scleroderma, Parkinson’s disease
• Functional GI disorders: IBS, functional dyspepsia
• Use of PPIs or H2 blockers for >3 months
• Structural conditions: Crohn’s disease with strictures, intestinal diverticula
• Immune compromise: HIV, organ transplantation, corticosteroid therapy
• Age > 65 (decline in motility and gastric acid)

Diagnosis

Diagnosing SIBO can be challenging because symptoms overlap with many other gastrointestinal disorders. A combination of clinical suspicion, breath testing, and, when necessary, invasive studies is used.

Breath tests (first‑line)

• Lactulose hydrogen breath test (LHBT) – Patient ingests 10 g lactulose; breath hydrogen and methane are measured every 15 minutes for up to 3 hours. An early rise (≤90 minutes) in hydrogen ≥20 ppm or methane ≥10 ppm suggests SIBO.
• Glucose hydrogen breath test (GHBT) – Glucose is absorbed in the proximal small bowel, so a rise in hydrogen/ methane indicates overgrowth in the duodenum or jejunum.

Both tests have sensitivities around 60‑80% and specificities ~70‑85% when performed under standardized conditions (fasting, no antibiotics/probiotics for 2 weeks, no smoking).

Direct aspirate culture (gold standard, rarely used)

A sample of jejunal fluid is obtained via endoscopy; bacterial counts ≥10⁵ CFU/mL are diagnostic. The procedure is invasive, costly, and not routinely performed, but may be indicated when breath tests are inconclusive or prior treatment has failed.

Additional investigations

• Complete blood count, iron studies, vitamin B12, folate – to identify malnutrition.
• Stool studies – rule out other causes of diarrhea (e.g., C. diff).
• Imaging (CT, MRI, abdominal ultrasound) – evaluate for strictures, masses, or blind loops.
• Motility testing – antroduodenal manometry when motility disorder is suspected.

Treatment Options

The therapeutic goal is to eradicate excess bacteria, restore normal motility, and prevent recurrence.

Antibiotic therapy

• Rifaximin – A non‑systemic, gut‑targeted antibiotic commonly used (550 mg PO three times daily for 14 days). Cure rates 60‑80% in meta‑analyses (Mayo Clinic, 2022).
• Combination therapy – For patients with methane‑dominant SIBO, adding neomycin (500 mg PO twice daily for 10 days) improves eradication.
• Alternative agents – Metronidazole, ciprofloxacin, or clarithromycin may be used when rifaximin is unavailable or contraindicated.

Repeat breath testing 4–6 weeks after treatment confirms eradication; if positive, a second course is often effective.

Prokinetic agents

When motility impairment is a key factor, drugs such as prucalopride, erythromycin low‑dose, or lysomotiftine (in Europe) help re‑establish the MMC and reduce recurrence.

Dietary modifications

• Low‑FODMAP diet – Reduces fermentable carbohydrates that feed bacteria. Studies show symptom improvement in 50‑70% of SIBO patients.
• Specific Carbohydrate Diet (SCD) – Eliminates disaccharides and most polysaccharides; may be useful for refractory cases.
• Elemental diet – A liquid formula composed of pre‑digested nutrients (e.g., 900 kcal/day for 2 weeks) starves bacterial overgrowth and can be used adjunctively with antibiotics.

Supplements & supportive care

• Vitamin B12 (injectable or high‑dose oral) if deficient.
• Iron, calcium, magnesium, and fat‑soluble vitamin supplementation as needed.
• Probiotics – evidence is mixed; a short course of a multi‑strain probiotic after antibiotics may help sustain a balanced microbiome.

Addressing underlying conditions

Effective treatment of diabetes, thyroid disease, or surgical correction of strictures is essential to prevent relapse.

Living with Small Intestinal Bacterial Overgrowth (SIBO)

Long‑term management focuses on symptom control, nutrition, and minimizing recurrence.

Daily management tips

• Meal timing – Eat smaller, more frequent meals (4‑6 per day) to avoid large boluses that can stagnate.
• Chew thoroughly – Proper mastication initiates digestion and reduces the load entering the small intestine.
• Stay hydrated – Aim for ≥2 L of water daily; adequate fluid helps maintain motility.
• Limit high‑FODMAP foods – Common culprits include onions, garlic, wheat, beans, certain fruits (apples, pears), and artificial sweeteners.
• Mindful antibiotic use – Avoid unnecessary broad‑spectrum antibiotics; they can disrupt the gut flora and predispose to SIBO.
• Physical activity – Moderate exercise (30 min most days) stimulates gastrointestinal motility.
• Stress management – Chronic stress impairs the MMC; techniques such as mindfulness, yoga, or cognitive‑behavioral therapy can be beneficial.
• Regular follow‑up – Schedule breath testing or labs every 6‑12 months, especially if symptoms recur.

Monitoring nutrition

Work with a registered dietitian familiar with SIBO. Track weight, energy levels, and any new deficiencies. A food‑symptom diary can reveal trigger foods.

Prevention

While not all cases are preventable, risk can be reduced through lifestyle and medical measures:

• Maintain optimal glycemic control if you have diabetes.
• Limit long‑term use of acid‑suppressing medications; discuss alternatives with your physician.
• Address constipation promptly – fiber (if tolerated), osmotic laxatives, or stool softeners.
• Practice good oral hygiene; poor dentition can increase oral bacteria that later colonize the gut.
• Consider periodic probiotic use after antibiotics, especially if you have a history of recurrent SIBO.
• Screen and treat underlying motility disorders early.

Complications

If untreated, SIBO can lead to several serious health issues:

• Nutrient malabsorption – leading to anemia (iron/B12), osteoporosis (calcium/vitamin D), and peripheral neuropathy.
• Weight loss and cachexia – especially in elderly or frail patients.
• Chronic diarrhea or constipation – can cause electrolyte imbalances, dehydration, and renal dysfunction.
• Increased intestinal permeability (“leaky gut”) – may contribute to systemic inflammation and autoimmune activation.
• Exacerbation of IBS or functional dyspepsia – making symptom control more difficult.
• Small bowel bacterial translocation – rare, but can cause bacteremia, especially in immunocompromised individuals.

When to Seek Emergency Care

---

Sources: Mayo Clinic, NIH National Institute of Diabetes and Digestive and Kidney Diseases, CDC, World Health Organization, Cleveland Clinic, Gut journal, American Journal of Gastroenterology (2022‑2024).